News

Upon exercise of this option and transition of the programme, GSK will assume responsibility for all development, manufacturing and commercialisation activities for the asset.  Adaptimmune will receive up

The drug showed a statistically-significant improvement in lung function in patients with moderate to very severe stable COPD compared against individual component that included either aclidinium bromide or formoterol.

The settlement with the US federal government is for resolving claims that the Danish multinational pharma failed to comply with the US Food and Drug Administration (FDA)-mandated Risk

The collaboration will seek to identify and develop Bicycles to treat rare blood disorders. Bicycles are a new therapeutic modality that combine attributes of antibodies, small molecules and

PATH also announced that several global experts in vaccine development and introduction have joined PATH CVIA to advance these critical vaccine efforts. “We are excited to continue our

Alecensa has significantly decreased  the risk of disease deterioration or death (progression-free survival, PFS) by 85% compared against chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small

Noctiva is a proprietary low-dose formulation of desmopressin acetate administered through a patent-protected intranasal delivery system. It is the first and only product approved by the U.S. Food

 Glioblastoma multiforme and anaplastic astrocytoma are the most common and most severe forms of non-metastatic brain cancer. According to the Central Brain Tumor Registry of the United States,

Keytruda has been approved as a monotherapy to treat locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy and adults who are not